Ronald I. Eisenstein

Ronald Eisenstein focuses his practice on advising biotechnology and pharmaceutical companies, research institutes, and universities on patent portfolio management, post-issuance strategies, dispute management and due diligence. He is also a member of the firm’s Life Sciences team.My focusI focus my practice on helping clients devise and execute strategies for managing their patent portfolios as well as navigate the changing patent landscape. I leverage my scientific background, extensive legal experience and business acumen to strategically counsel clients on upcoming legal and business trends. Key areas of concentration for me include: immune modulation including antibodies; gene therapy; cancer vaccines; angiogenesis modulation; personalized medicine, including diagnostics, proteomics, biomarkers, companion diagnostics and related systems; synthetic biology; small molecules; magnetic resonance imaging; and primate lentiviruses. Patent StrategiesI’ve worked with many clients to develop and implement a wide variety of patent strategies including strategic patent procurement, portfolio development, competitive intelligence and analysis, licensing and enforcement of the patents. I also counsel clients on alternative dispute resolution tactics and manage such approaches, especially when the outcome aligns with a company’s business objectives. Patent ProsecutionI focus on prosecution of biotechnology, medical and chemical cases and emphasize strategic management of my clients’ intellectual property portfolios. Post-IssuanceI help clients understand, and effectively use post-issuance procedures such as oppositions, interferences and inter partes reviews-both offensively and defensively. In addition, I provide freedom-to-operate guidance to clients as well as due diligence for acquisitions and financing. Ronald Eisenstein focuses his practice on advising biotechnology and pharmaceutical companies, research institutes, and universities on patent portfolio management, post-issuance strategies, dispute management and due diligence. He is also a member of the firm’s Life Sciences team.